Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Elasomeran
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : As part of the agreement, ASOFARMA will collaborate with Moderna in the management of supply contracts already in force, as well as in vaccine registration processes, support for pharmacovigilance activities, and generation of new agreements for the avai...
Brand Name : Spikevax
Molecule Type : Vaccine
Upfront Cash : Undisclosed
February 23, 2022
Lead Product(s) : Elasomeran
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Elasomeran
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Adium Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Moderna Expands Global Footprint Through Commercial Partnership with Adium in Latin America
Details : Agreement with Adium Pharma will support the commercialization of the Moderna COVID-19 vaccine, Spikevax across Latin America. The agreement covers 18 countries in Latin America, including Brazil, Mexico, Colombia, and Argentina.
Brand Name : Spikevax
Molecule Type : Vaccine
Upfront Cash : Undisclosed
February 22, 2022
Lead Product(s) : Elasomeran
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Adium Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Study Phase : Approved
Recipient : PharmaMar
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Pharmamar Signs a New Agreement with Adium Pharma S.A. to Commercialize Yondelis® in Latin America
Details : Through agreement, Adium will be able to commercialize the marine-derived anticancer drug Yondelis (trabectedin), which is used in the treatment of soft tissue sarcoma and relapsed ovarian cancer.
Brand Name : Yondelis
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 27, 2020
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : PharmaMar
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?